These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35994576)

  • 21. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.
    Stalter RM; Dong TQ; Hendrix CW; Palanee-Phillips T; van der Straten A; Hillier SL; Kiweewa FM; Mgodi NM; Marzinke MA; Bekker LG; Soto-Torres L; Baeten JM; Brown ER;
    J Infect Dis; 2024 Apr; 229(4):1158-1165. PubMed ID: 38099506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides.
    Fetherston SM; Malcolm RK; Woolfson AD
    Ther Deliv; 2010 Dec; 1(6):785-802. PubMed ID: 22834014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
    Doggett EG; Lanham M; Wilcher R; Gafos M; Karim QA; Heise L
    J Int AIDS Soc; 2015; 18(1):20536. PubMed ID: 26700845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Women's motivations for participating in the dapivirine vaginal ring open label extension study.
    Naidoo K; Montgomery ET; Katz AWK; Garcia M; Naidoo S; Mansoor LE
    AIDS Care; 2024 Mar; 36(3):326-342. PubMed ID: 37734338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between vaginal ring use and intimate partner violence and social harms: formative research outcomes from the CHARISMA study in Johannesburg, South Africa.
    Hartmann M; Palanee-Phillips T; O'Rourke S; Adewumi K; Tenza S; Mathebula F; Wagner D; Ayub A; Montgomery ET
    AIDS Care; 2019 Jun; 31(6):660-666. PubMed ID: 30309246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical microbicides for preventing sexually transmitted infections.
    Obiero J; Ogongo P; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007961. PubMed ID: 33719075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine.
    Major I; Boyd P; Kilbourne-Brook M; Saxon G; Cohen J; Malcolm RK
    Contraception; 2013 Jul; 88(1):58-66. PubMed ID: 23177261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women.
    Shapley-Quinn MK; Laborde N; Luecke E; Hoesley C; Salata RA; Johnson S; Nel A; Soto-Torres L; Chen BA; van der Straten A
    AIDS Patient Care STDS; 2022 Mar; 36(3):97-105. PubMed ID: 35289688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing.
    das Neves J; Martins JP; Sarmento B
    Adv Drug Deliv Rev; 2016 Aug; 103():20-32. PubMed ID: 26732684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women.
    Nel A; Haazen W; Nuttall J; Romano J; Rosenberg Z; van Niekerk N
    AIDS; 2014 Jun; 28(10):1479-87. PubMed ID: 24901365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.
    Bunge KE; Levy L; Szydlo DW; Zhang J; Gaur AH; Reirden D; Mayer KH; Futterman D; Hoesley C; Hillier SL; Marzinke MA; Hendrix CW; Gorbach PM; Wilson CM; Soto-Torres L; Kapogiannis B; Nel A; Squires KE;
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):135-139. PubMed ID: 31929401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.
    Katz AWK; Naidoo K; Reddy K; Chitukuta M; Nabukeera J; Siva S; Zimba C; Montgomery ET
    AIDS Behav; 2020 Aug; 24(8):2387-2399. PubMed ID: 31980993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex.
    Laborde ND; Pleasants E; Reddy K; Atujuna M; Nakyanzi T; Chitukuta M; Naidoo S; Palanee-Phillips T; Baeten JM; Montgomery ET;
    AIDS Behav; 2018 Feb; 22(2):437-446. PubMed ID: 29151197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
    Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
    J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
    Pleasants E; Tauya T; Reddy K; Mirembe BG; Woeber K; Palanee-Phillips T; Zimba C; Atujuna M; Montgomery ET;
    AIDS Behav; 2020 Mar; 24(3):866-880. PubMed ID: 31111297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WHO guidance grounded in a comprehensive approach to sexual and reproductive health and human rights: topical pre-exposure prophylaxis.
    Lusti-Narasimhan M; Khosla R; Baggaley R; Temmerman M; McGrory E; Farley T
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19279. PubMed ID: 25224620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
    Reddy K; Kelly C; Brown ER; Jeenarain N; Naidoo L; Siva S; Bekker LG; Nair G; Makanani B; Chinula L; Mgodi N; Chirenje Z; Kiweewa FM; Marrazzo J; Bunge K; Soto-Torres L; Piper J; Baeten JM; Palanee-Phillips T;
    AIDS; 2020 Mar; 34(4):559-567. PubMed ID: 31764068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States.
    van der Straten A; Panther L; Laborde N; Hoesley CJ; Cheng H; Husnik MJ; Horn S; Nel A; Soto-Torres L; Chen BA
    AIDS Behav; 2016 Nov; 20(11):2644-2653. PubMed ID: 26837628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.
    Browne EN; Brown ER; Palanee-Phillips T; Reddy K; Naidoo L; Jeenarain N; Nair G; Husnik MJ; Singh D; Scheckter R; Soto-Torres L; Baeten JM; van der Straten A;
    J Acquir Immune Defic Syndr; 2022 Aug; 90(4):418-424. PubMed ID: 35344520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Women's experience receiving drug feedback and adherence counseling in MTN-025/HOPE - an HIV Prevention open-label trial of the Dapivirine Vaginal Ring.
    Katz AWK; Balán IC; Reddy K; Etima J; Weber K; Tauya T; Atujuna M; Scheckter R; Ngure K; Soto-Torres L; Mgodi N; Palanee-Phillips T; Baeten JM; van der Straten A
    AIDS Behav; 2022 Nov; 26(11):3607-3619. PubMed ID: 35536519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.